HomeInsightsStock Comparison

Concord Biotech Ltd vs Themis Medicare Ltd Stock Comparison

Concord Biotech Ltd vs Themis Medicare Ltd Stock Comparison

Last Updated on: Jul 19, 2025

Key Highlights

  • The Latest Trading Price of Concord Biotech Ltd is ₹ 1893 as of 18 Jul 15:30.
  • The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 51.7 on March 2024 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Themis Medicare Ltd changed from 8.9 on March 2020 to 46.3 on March 2024 . This represents a CAGR of 39.07% over 5 years.
  • The Market Cap of Concord Biotech Ltd changed from ₹ 15922 crore on March 2024 to ₹ 15922 crore on March 2024 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 220.51 crore on March 2020 to ₹ 2015 crore on March 2024 . This represents a CAGR of 55.67% over 5 years.
  • The revenue of Concord Biotech Ltd for the Mar '25 is ₹ 439.27 crore as compare to the Dec '24 revenue of ₹ 260.78 crore. This represent the growth of 68.44% The revenue of Themis Medicare Ltd for the Mar '25 is ₹ 73.25 crore as compare to the Dec '24 revenue of ₹ 94.83 crore. This represent the decline of -22.76%.
  • The ebitda of Concord Biotech Ltd for the Mar '25 is ₹ 198.26 crore as compare to the Dec '24 ebitda of ₹ 114.51 crore. This represent the growth of 73.14% The ebitda of Themis Medicare Ltd for the Mar '25 is ₹ -6.14 crore as compare to the Dec '24 ebitda of ₹ 6.99 crore. This represent the decline of -187%.
  • The net profit of Concord Biotech Ltd changed from ₹ 54.49 crore to ₹ 140.39 crore over 8 quarters. This represents a CAGR of 60.51% The net profit of Themis Medicare Ltd changed from ₹ 18.19 crore to ₹ -9.66 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Concord Biotech Ltd changed from 24.05 % on March 2020 to 30.03 % on March 2024 . This represents a CAGR of 4.54% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 10.11 % on March 2020 to 18.59 % on March 2024 . This represents a CAGR of 12.96% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Concord Biotech Ltd

  • Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
  • Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
  • Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.

About Themis Medicare Ltd

  • Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
  • The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
  • Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
  • The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

Concord Biotech Ltd News Hub

News

Concord Biotech acquires 75% stake in Stellon Biotech

Concord Biotech has made an equity investment of USD 1,500 in Stellon Biotech Inc. This in...

Read more

02 Jul 2025 12:10

News

Concord Biotech edges higher on value buying; trades above 100-day SMA

The scrip had declined 15.63% in seven sessions to end at Rs 1,780.75 yesterday, from its ...

Read more

25 Jun 2025 11:40

News

Concord Biotech's API facility completes USFDA inspection

Concord Biotech has received an Establishment Inspection Report (EIR) from the US Food and...

Read more

24 Jun 2025 19:06

News

Board of Concord Biotech recommends final dividend

Concord Biotech announced that the Board of Directors of the Company at its meeting held o...

Read more

30 May 2025 11:14

News

Concord Biotech to announce Quarterly Result

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 202...

Read more

24 May 2025 18:40

News

Concord Biotech gets US FDA nod for marketing multiple sclerosis drug Teriflunomide

Teriflunomide tablets are used for the treatment of patients with relapsing forms of multi...

Read more

09 Apr 2025 09:18

Themis Medicare Ltd News Hub

News

Board of Themis Medicare recommends final dividend

Themis Medicare announced that the Board of Directors of the Company at its meeting held o...

Read more

21 May 2025 11:37

News

Themis Medicare to declare Quarterly Results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 20 May 202...

Read more

16 May 2025 16:53

News

Themis Medicare to discuss results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 14 Februar...

Read more

11 Feb 2025 10:53

News

Themis Medicare to discuss results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 25 October...

Read more

19 Oct 2024 10:22

News

Themis Medicare to hold board meeting

Themis Medicare will hold a meeting of the Board of Directors of the Company on 26 July 20...

Read more

17 Jul 2024 09:49

News

Board of Themis Medicare recommends final dividend

Themis Medicare announced that the Board of Directors of the Company at its meeting held o...

Read more

15 May 2024 10:44

SWOT Analysis Of Concord Biotech Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Themis Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Concord Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Themis Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Concord Biotech Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Concord Biotech Ltd or Themis Medicare Ltd?

Market cap of Concord Biotech Ltd is 19,811 Cr while Market cap of Themis Medicare Ltd is 1,156 Cr

What are the key factors driving the stock performance of Concord Biotech Ltd and Themis Medicare Ltd?

The stock performance of Concord Biotech Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Biotech Ltd and Themis Medicare Ltd?

As of July 19, 2025, the Concord Biotech Ltd stock price is INR ₹1893.75. On the other hand, Themis Medicare Ltd stock price is INR ₹125.65.

How do dividend payouts of Concord Biotech Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Concord Biotech Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions